Ross Kirsty, Pailler Emma, Faugeroux Vincent, Taylor Melissa, Oulhen Marianne, Auger Nathalie, Planchard David, Soria Jean-Charles, Lindsay Colin R, Besse Benjamin, Vielh Philippe, Farace Françoise
a INSERM, U981 "Identification of Molecular Predictors and new Targets for Cancer Treatment" , F-94805 , VILLEJUIF , France.
b Gustave Roussy, Université Paris-Saclay , "Circulating Tumor Cells" Translational Platform, CNRS UMS3655 - INSERM US23 AMMICA, F-94805 , VILLEJUIF , France.
Expert Rev Mol Diagn. 2015;15(12):1605-29. doi: 10.1586/14737159.2015.1111139. Epub 2015 Nov 13.
In non-small-cell lung cancer (NSCLC), genotyping tumor biopsies for targetable somatic alterations has become routine practice. However, serial biopsies have limitations: they may be technically difficult or impossible and could incur serious risks to patients. Circulating tumor cells (CTCs) offer an alternative source for tumor analysis that is easily accessible and presents the potential to identify predictive biomarkers to tailor therapies on a personalized basis. Examined here is our current knowledge of CTC detection and characterization in NSCLC and their potential role in EGFR-mutant, ALK-rearranged and ROS1-rearranged patients. This is followed by discussion of the ongoing issues such as the question of CTC partnership as diagnostic tools in NSCLC.
在非小细胞肺癌（NSCLC）中，对肿瘤活检进行基因分型以检测可靶向的体细胞改变已成为常规操作。然而，系列活检存在局限性：它们在技术上可能困难或无法进行，并且可能给患者带来严重风险。循环肿瘤细胞（CTC）为肿瘤分析提供了另一种易于获取的来源，并且有潜力识别预测性生物标志物，从而实现个性化治疗。本文探讨了我们目前对NSCLC中CTC检测、特征及其在表皮生长因子受体（EGFR）突变、间变性淋巴瘤激酶（ALK）重排和ROS1重排患者中的潜在作用的了解。随后讨论了当前存在的问题，例如CTC作为NSCLC诊断工具的相关性问题。
